<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02253992</url>
  </required_header>
  <id_info>
    <org_study_id>CA186-107</org_study_id>
    <secondary_id>2014-002241-22</secondary_id>
    <nct_id>NCT02253992</nct_id>
  </id_info>
  <brief_title>An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and
      tolerable when they are given together.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2014</start_date>
  <completion_date type="Anticipated">September 27, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 26, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by the rate of adverse events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 100 days after last dose of treatment</time_frame>
    <description>Safety as measured by the rate of adverse events (AEs) and Serious Adverse Events (SAEs), is the primary endpoint of this Phase 1/2 study. All subjects who receive at least one (full or partial) dose of Urelumab or Nivolumab will be evaluated for safety during treatment and for up to 100 days in follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>Every 8 weeks for Cycle 1 through Cycle 6 then every 12 weeks thereafter for approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Every 8 weeks for Cycle 1 through Cycle 6 then every 12 weeks thereafter for approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Every 8 weeks for Cycle 1 through Cycle 6 then every 12 weeks thereafter for approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate (PFSR)</measure>
    <time_frame>Every 8 weeks for Cycle 1 through Cycle 6 then every 12 weeks thereafter for approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of Urelumab,(µg/mL)</measure>
    <time_frame>Cycles 1, 2, 3, 4, 6, and followup Days up to 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) of Urelumab, (hr)</measure>
    <time_frame>Cycles 1, 2, 3, 4, 6, and followup Days up to 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval (AUCTAU) of Urelumab (µg.hr/mL)</measure>
    <time_frame>Cycles 1, 2, 3, 4, 6, and followup Days up to 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUCinf) of Urelumab (µg.hr/mL)</measure>
    <time_frame>Cycles 1, 2, 3, 4, 6, and followup Days up to 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT) of Urelumab (L/day)</measure>
    <time_frame>Cycles 1, 2, 3, 4, 6, and followup Days up to 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) of Urelumab</measure>
    <time_frame>Cycles 1, 2, 3, 4, 6, and followup Days up to 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (t1/2) of Urelumab</measure>
    <time_frame>Cycles 1, 2, 3, 4, 6, , and followup Days up to 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Cmin) of Urelumab (µg/mL)</measure>
    <time_frame>Cycles 1, 2, 3, 4, 6, and followup Days up to 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of specific anti-drug antibodies (ADA) to Urelumab and Nivolumab</measure>
    <time_frame>Cycles 1, 2, 3, 4, 6, and followup Days up to 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug Antibody (ADA) status of the subject in response to Urelumab and Nivolumab</measure>
    <time_frame>Cycles 1, 2, 3, 4, 6, and followup Days up to 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nivolumab end of Infusion concentration (EOI)</measure>
    <time_frame>Cycles 1, 2, 3, 4, 6, and followup Days up to 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Cmin) of Nivolumab (µg/mL)</measure>
    <time_frame>Cycles 1, 2, 3, 4, 6, and followup Days up to 100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Advanced B-cell NHL</condition>
  <arm_group>
    <arm_group_label>Dose Escalation and Cohort expansion: Urelumab + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab followed by Urelumab
Nivolumab every 2 weeks up to 12 cycles and Urelumab every 4 weeks up to 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Urelumab</intervention_name>
    <arm_group_label>Dose Escalation and Cohort expansion: Urelumab + Nivolumab</arm_group_label>
    <other_name>BMS-663513</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Dose Escalation and Cohort expansion: Urelumab + Nivolumab</arm_group_label>
    <other_name>BMS-936558</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  For Dose Escalation:

               -  Subjects with any previously treated advanced (metastatic or refractory) solid
                  tumor type and B-cell non-Hodgkin lymphoma

          -  For Cohort Expansion:

               -  Subjects must have a previously treated advanced solid tumor or B cell
                  non-Hodgkin's lymphoma to be eligible

               -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

               -  For certain subjects, willing and able to provide pre-treatment and on-treatment
                  fresh tumor biopsy

               -  Women of child-bearing potential and men must use an acceptable method of
                  contraception during treatment and for 23 weeks after treatment for women and 31
                  weeks for men

        Exclusion Criteria:

          -  Known central nervous system metastases or central nervous system as the only source
             of disease

          -  Other concomitant malignancies (with some exceptions per protocol)

          -  Active, known or suspected autoimmune disease

          -  Uncontrolled or significant cardiovascular disease

          -  History of hepatitis (B or C)

          -  History of active or latent tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University School Of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shivaani Kummar, Site 0016</last_name>
      <phone>650-498-8604</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikhil Khushalani, Site 0001</last_name>
      <phone>813-745-4617</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Luke, Site 0017</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Sharfman, Site 0006</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick A. Ott, Site 0009</last_name>
      <phone>617-724-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick A. Ott, Site 0015</last_name>
      <phone>617-632-9285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick A. Ott, Site 0005</last_name>
      <phone>617-632-5055</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Weber, Site 0020</last_name>
      <phone>212-263-4428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Segal, Site 0007</last_name>
      <phone>646-888-3359</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Ferris, Site 0003</last_name>
      <phone>412-623-7957</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Md Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vassiliki Papadimitrakopoulou, Site 0002</last_name>
      <phone>713-792-6363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0014</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0013</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0012</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0011</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Schadendorf, Site 0008</last_name>
      <phone>+492017234342</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria De Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>September 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

